{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:40:40Z","timestamp":1759970440864,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone involvement, a myeloma-defining event, represents a major source of morbidity for patients. Key goals for the management of myeloma precursor conditions include (1) identifying patients at the highest risk for progression to MM with bone involvement and (2) differentiating precursor states from active myeloma requiring treatment. Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)-CT with [18F]fluorodeoxyglucose (FDG) have improved sensitivity for the detection of myeloma bone disease compared to traditional skeletal surveys, and such advanced imaging also provides this field with better tools for detecting early signs of progression. Herein, we review the data supporting the use of advanced imaging for both diagnostics and prognostication in myeloma precursor conditions.<\/jats:p>","DOI":"10.3390\/diagnostics15020215","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:04:12Z","timestamp":1737345852000},"page":"215","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-3005","authenticated-orcid":false,"given":"Kara I.","family":"Cicero","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"},{"name":"Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"},{"name":"Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Kwok","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"},{"name":"Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"},{"name":"Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"},{"name":"Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Washington, Seattle, WA 98115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-1593","authenticated-orcid":false,"given":"Majid","family":"Chalian","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Washington, Seattle, WA 98115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-7094","authenticated-orcid":false,"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"},{"name":"Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2021-152333","article-title":"Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study","volume":"138","author":"Kristinsson","year":"2021","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Aspelund","year":"2023","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: Impact on early progression","volume":"32","author":"Isola","year":"2018","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: Predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/bjh.17088","article-title":"Diagnostic performance of (18) F-FDG-PET\/CT compared to standard skeletal survey for detecting bone destruction in smouldering multiple myeloma: Time to move forward","volume":"193","author":"Hill","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2174\/1573405617666210126155129","article-title":"Skeletal Survey in Multiple Myeloma: Role of Imaging","volume":"17","author":"Spinnato","year":"2021","journal-title":"Curr. Med. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00256-018-3066-6","article-title":"Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states","volume":"48","author":"Simeone","year":"2019","journal-title":"Skeletal Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41408-020-00360-9","article-title":"The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma","volume":"10","author":"Gavriatopoulou","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/ajh.25846","article-title":"Role of imaging in multiple myeloma","volume":"95","author":"Baffour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1995.13.1.251","article-title":"Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"13","author":"Moulopoulos","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jmri.28067","article-title":"Magnetic Resonance Imaging Versus Computed Tomography for Three-Dimensional Bone Imaging of Musculoskeletal Pathologies: A Review","volume":"56","author":"Florkow","year":"2022","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e27131","DOI":"10.1097\/MD.0000000000027131","article-title":"Role of whole-body diffusion-weighted imaging in evaluation of multiple myeloma","volume":"100","author":"Wang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.18232","article-title":"Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage","volume":"199","author":"Wennmann","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25254","DOI":"10.18632\/oncotarget.25402","article-title":"Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients","volume":"9","author":"Wennmann","year":"2018","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wennmann, M., Hielscher, T., Kintzel\u00e9, L., Menze, B.H., Langs, G., Merz, M., Sauer, S., Kauczor, H.U., Schlemmer, H.P., and Delorme, S. (2021). Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers, 13.","DOI":"10.3390\/cancers13050961"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"116857","DOI":"10.1016\/j.bone.2023.116857","article-title":"Identification of focal lesion characteristics in MRI which indicate presence of corresponding osteolytic lesion in CT in patients with multiple myeloma","volume":"175","author":"Hildenbrand","year":"2023","journal-title":"Bone"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wennmann, M., Hielscher, T., Kintzel\u00e9, L., Menze, B.H., Langs, G., Merz, M., Sauer, S., Kauczor, H.U., Schlemmer, H.P., and Delorme, S. (2020). Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria. Cancers, 12.","DOI":"10.3390\/cancers12092537"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ejrad.2014.03.005","article-title":"Infiltration patterns in monoclonal plasma cell disorders: Correlation of magnetic resonance imaging with matched bone marrow histology","volume":"83","author":"Andrulis","year":"2014","journal-title":"Eur. J. Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/leu.2013.244","article-title":"Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance","volume":"28","author":"Hillengass","year":"2014","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2014.75","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","author":"Merz","year":"2014","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.acra.2021.06.015","article-title":"Evaluation of Diffuse Bone Marrow Infiltration Pattern in Monoclonal Plasma Cell Diseases by Quantitative Whole-body Magnetic Resonance Imaging","volume":"29","author":"Sun","year":"2022","journal-title":"Acad. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: Identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pi\u00f1eiro-Fiel, M., Moscoso, A., Pubul, V., Ruibal, \u00c1., Silva-Rodr\u00edguez, J., and Aguiar, P. (2021). A Systematic Review of PET Textural Analysis and Radiomics in Cancer. Diagnostics, 11.","DOI":"10.3390\/diagnostics11020380"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.117.196063","article-title":"Preclinical Development of CD38-Targeted [(89)Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma","volume":"59","author":"Ghai","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00256-020-03529-2","article-title":"Marrow uptake on FDG PET\/CT is associated with progression from smoldering to symptomatic multiple myeloma","volume":"50","author":"Amini","year":"2021","journal-title":"Skeletal Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Takahashi, M.E.S., Mosci, C., Souza, E.M., Brunetto, S.Q., Etchebehere, E., Santos, A.O., Camacho, M.R., Miranda, E., Lima, M.C.L., and Amorim, B.J. (2019). Proposal for a Quantitative (18)F-FDG PET\/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-52740-2"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clml.2021.03.014","article-title":"Progression to Symptomatic Multiple Myeloma Predicted by Texture Analysis-Derived Parameters in Patients Without Focal Disease at (18)F-FDG PET\/CT","volume":"21","author":"Ripani","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"22486","DOI":"10.1021\/acsomega.3c00624","article-title":"(89)Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas","volume":"8","author":"Michel","year":"2023","journal-title":"ACS Omega"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1021\/acs.molpharmaceut.1c00628","article-title":"Annotating BCMA Expression in Multiple Myelomas","volume":"19","author":"Wei","year":"2022","journal-title":"Mol. Pharm."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/215\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:31:16Z","timestamp":1759919476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["diagnostics15020215"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15020215","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2025,1,18]]}}}